Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.

[1]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[2]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Mei‐Kang Yuan,et al.  Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma. , 2013, Journal of the Chinese Medical Association : JCMA.

[4]  C. Schaefer-Prokop,et al.  Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. , 2012, Lung cancer.

[5]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[6]  Liang-an Chen,et al.  Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease , 2011, Case Reports in Oncology.

[7]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[8]  F. Kaye,et al.  Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[10]  M. Fukuoka,et al.  Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Chong-Jen Yu,et al.  Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Shi‐Xu Jiang,et al.  Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease , 2010, Cancer Chemotherapy and Pharmacology.

[13]  K. Kiura,et al.  Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[15]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[16]  L. Paz-Ares,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[17]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[18]  H. Kato,et al.  Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. , 2008, American journal of respiratory and critical care medicine.

[19]  G. Tortora,et al.  Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs , 2008, British Journal of Cancer.

[20]  Kazuya Suzuki,et al.  Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report , 2007, Journal of medical case reports.

[21]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[22]  M. Fukuoka,et al.  Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[24]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[26]  M. Ebina,et al.  Severe acute interstitial pneumonia and gefitinib , 2003, The Lancet.

[27]  A. Gemma,et al.  Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  M. Nishimura,et al.  Recurrent gefitinib-induced interstitial lung disease. , 2008, Internal medicine.

[29]  S. Sone,et al.  Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. , 2005, Oncology research.